IntegriChain's Access Insights Conference Sells Out for Second Consecutive Year
Record turnout, expanded sponsor roster, and customer award recognitions mark milestone 20th anniversary event at The Mayflower Hotel in Washington, D.C.
PHILADELPHIA, Oct. 22, 2026 /PRNewswire/ -- IntegriChain, the leading provider of revenue optimization technology and consulting for the pharmaceutical industry, today reflected on a landmark Access Insights Conference 2026, held October 19–21 at The Mayflower Hotel, in Washington, D.C. For the second year in a row, the conference sold out, underscoring growing demand among pharmaceutical manufacturers for insight into an increasingly complex commercialization and market access landscape.
This year's conference also marked a milestone: IntegriChain's 20th anniversary of supporting biopharma manufacturers in patient access and net revenue optimization.
Sponsors
Access Insights 2026 was supported by a strong roster of commercial sponsors:
- Titanium Sponsor: GiftHealth
- Additional Sponsors: GoodRx, Asembia, Second Sight Solutions, PHIL, Medfuse, Lighthouse AI, Purple Lab, RxWare, Courier Health, and BioCareSD
Agenda Highlights
The conference opened Monday afternoon with an Executive Summit led by IntegriChain CEO Josh Halpern, whose session, "AI at the Speed of Access," explored how artificial intelligence is reshaping market access faster than the industry anticipated, and what that acceleration means for manufacturers as IntegriChain marks its 20th anniversary. Bill Roth, SVP of Consulting & Advisory, followed with a keynote on "The Great Re-Pricing," examining the fragmenting payer market and the new realities it is creating for pricing and access strategy. The afternoon concluded with powerhouse panels on evolving healthcare policy, market dynamics, and commercialization strategy.
Tuesday and Wednesday featured expert panels and Hot Topics tracks spanning three key industry shifts:
- Pricing, Policy, and Reimbursement – navigating healthcare policy shifts, affordability program transitions, GTN modeling innovation, and IRA/340B operational readiness
- Data and Technology – AI/ML innovation, next-generation data architecture, master data management, and affordability program controls
- Business and Strategy – transforming net revenue access, pre-commercialization decisions, commercial data strategy, and portfolio mix optimization
Customer Award Winners
IntegriChain also recognized standout customers for leadership and innovation in pharmaceutical commercialization:
- Commercialization Vision Award: Galderma
- Lighthouse Award: Incyte
- Zero to Launch Award: Cytokinetics
- ICyte Power User Award: Jim Peck, Merck
- Tina Patel Shining Light Award: Michelle Cerutti, Apellis
20th Anniversary
IntegriChain kicked off its 20th anniversary celebration with a cocktail reception on Tuesday, October 20th. Co-founders Kevin Leneinger and Josh Halpern, IntegriChain's current CEO, took the stage to deliver inspiring remarks and celebrate the company's remarkable 20-year journey. IntegriChain is launching a multi-channel campaign celebrating two decades of helping biopharma manufacturers turn commercialization complexity into clarity. Through LinkedIn, YouTube, client and employee stories, and thought leadership, the campaign highlights IntegriChain's role in supporting the industry from a spreadsheet-driven past to a more connected, real-time future. The anniversary serves not only as a reflection on the company's history, but as a launchpad for what comes next in helping life sciences teams improve access, performance, and confidence across the full commercialization lifecycle.
"Twenty years in, and this community keeps proving there's nothing more valuable than getting in a room together to solve the hardest problems in access," said Josh Halpern, CEO of IntegriChain. "Selling out two years running tells us we're delivering exactly what this industry needs right now."
About IntegriChain
IntegriChain delivers biopharma's only comprehensive data-driven commercialization platform from strategy to operational execution, connecting the commercial, financial, and operational dimensions of drug access and profitability. Our ICyte® Platform integrates technology, data, consulting, and managed services to unify critical workflows, replacing manual processes with integrated analytics and precision controls.
Biopharma relies on IntegriChain to optimize patient access and net revenue performance, reduce leakage, and strengthen compliance, ensuring every life-changing therapy reaches patients with speed, affordability, and sustainability. Backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in healthcare and technology.
IntegriChain is headquartered in Philadelphia, PA, with a location in Pune, India.
Media Contact
Brandy Jensen, Senior Director/Co-Head, Marketing
IntegriChain
[email protected]
SOURCE IntegriChain, Inc.
Share this article